Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of MTBVAC

NCT05947890 is registered in ClinicalTrials.gov with HIV Vaccine Trials Network as lead sponsor.

NCT NCT05947890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of MTBVAC
Lead sponsor
HIV Vaccine Trials Network
Phase
Phase 2
Overall status
Recruiting
Start date
January 30, 2024
Completion date
April 5, 2027
Enrollment
276 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv i infection, tuberculosis